Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Pembrolizumab Induces Robust Responses in PD-L1-positive NSCLC

June 6th 2014

The anti-PD-1 humanized antibody pembrolizumab has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive NSCLC.

Necitumumab Delivers Rare Survival Benefit in Squamous NSCLC

June 6th 2014

Adding necitumumab to standard of care with gemcitabine-cisplatin significantly improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small-cell lung cancer of squamous histology.

Dr. Ramalingam on the Results of the Phase III REVEL Study in NSCLC

June 5th 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses the results of the phase III REVEL study in NSCLC.

Dr. Curran on the Effect of Clinical Trial Enrollment on NSCLC Patients

June 4th 2014

Walter J. Curran, Jr, MD, discusses a report that examined the effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation.

Dr. Spigel Discusses MPDL3280A Development in Lung Cancer

June 3rd 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials involving MPDL3280A in lung cancer.

CO-1686 Continues to Show Promising Results in Treatment-Resistant NSCLC

June 1st 2014

The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).

Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC

June 1st 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Ramucirumab Modestly Improves Survival in Advanced NSCLC

June 1st 2014

Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer.

2nd Annual Giants of Cancer Care Awards Honor Leading Researchers

May 30th 2014

The ballots are in, and 16 leading researchers whose discoveries have propelled the field of cancer treatment forward will be honored during the 2014 Giants of Cancer Care award ceremony on May 30 at Riva Restaurant on Navy Pier in Chicago.

CO-1686 Receives Breakthrough Designation for EGFR T790M-Positive NSCLC

May 20th 2014

CO-1686 has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic T790M mutation-positive NSCLC who have received at least one prior line of EGFR-targeted therapy.

As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes

May 14th 2014

In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).

AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC

May 14th 2014

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

MEDCAC Ruling on Lung Cancer Screening

May 1st 2014

The MEDCAC ruling will likely lead to non-coverage of lung cancer screening with low dose CT scans for Medicare and Medicaid beneficiaries.

New PER Conference Debuts With Format Aimed at Pressing Clinical Issues

May 1st 2014

Leading experts in the rapidly evolving field of lung cancer treatment assembled to offer their perspectives on the latest research and provide clinical insights for practitioners dealing with challenging cases.

Tissue Truly Is the Issue in Advanced Non-Small Cell Lung Cancer

April 30th 2014

The pathologic analysis of lung cancer has become increasingly complex, calling for continued attention to improving the accuracy of the assessment and reducing the amount of tissue required.

FDA Approves Ceritinib for ALK-Positive NSCLC

April 29th 2014

The FDA has approved the next-generation ALK inhibitor ceritinib as a treatment for ALK-positive patients with metastatic non-small cell lung cancer following treatment with crizotinib.

Dr. Halmos on the Impact of EGFR Inhibitors on the Treatment of Lung Cancer

April 28th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the impact of EGFR inhibitors on the treatment of lung cancer.

Advances in Immunotherapy for the Treatment of Non-Small Cell Lung Cancer

April 25th 2014

The treatment decisions for NSCLC are primarily dependent on the patient's performance status, extent of disease, and histological subtype. Significant developments in the area of targeted therapies have changed the treatment paradigm for NSCLC.

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

April 24th 2014

Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.

Pancoast Tumors of the Lung: Improved Results

April 16th 2014

Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.

NEXT PAGE
PREVIOUS PAGE